HCA
TCRX icon

Heck Capital Advisors’s TScan Therapeutics TCRX Stock Holding History

Heck Capital Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,120
Closed -$61.2K – 725
2024
Q4 		$61.2K Buy
+20,120
New +$91.2K ﹤0.01% 340

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Heck Capital Advisors's TCRX Position: Q1 2025 in Review

Heck Capital Advisors sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 20,120 shares — an estimated $61.2K sold.

Heck Capital Advisors first reported a position in TCRX in Q4 2024 and held it in 1 quarter. The position peaked at $61.2K in Q4 2024. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • Heck Capital Advisors reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 20,120 TScan Therapeutics shares in Q1 2025, an estimated $61.2K.
  • Heck Capital Advisors first reported a position in TScan Therapeutics in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's TScan Therapeutics position peaked at $61.2K in Q4 2024.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.